Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 7 · below the Ichimoku cloud · RSI 42 · MACD below its signal
None of the 29 investors followed here reported a position in AIFF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a AIFF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Mar 9, 2026 | Decaprio DavidPresident | Stock Award(Grant) at price 0.00 per share. | 44.9K | — |
| Mar 9, 2026 | Lipschitz GregoryChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 66K | — |
| Oct 21, 2025 | Windsor Private Capital Limited PartnershipBeneficial Owner of more than 10% of a Class of Security | Sale at price 2.07 - 2.46 per share. | 130.8K | $290.19K |
| Oct 16, 2025 | Windsor Private Capital Limited PartnershipBeneficial Owner of more than 10% of a Class of Security | Sale at price 2.55 - 2.74 per share. | 102.7K | $269.15K |
| Oct 13, 2025 | Windsor Private Capital Limited PartnershipBeneficial Owner of more than 10% of a Class of Security | Sale at price 2.65 - 2.94 per share. | 166.6K | $456.68K |
| Oct 21, 2024 | Johnson David IanOfficer and Director | Stock Award(Grant) at price 0.00 per share. | 557.9K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.1 | -19.5 | 211.4 | 2.8 | -21.0 | -31.6 | -11.6 | 4.7 | 36.6 | -28.8 | +23.9% | ||
| 2025 | 24.2 | 35.9 | -12.1 | -18.6 | -3.1 | -8.7 | -1.8 | -4.7 | 9.8 | -35.7 | -7.5 | -49.1 | −66.8% |
| 2024 | 20.1 | 4.4 | 63.2 | -19.9 | -16.2 | -10.8 | 2.4 | -38.4 | -22.4 | 1.6 | -1.0 | -13.4 | −47.7% |
| 2023 | 20.8 | 32.8 | -62.3 | 55.2 | -17.8 | -16.2 | -6.5 | 10.3 | -18.8 | -36.9 | 53.0 | -32.7 | −64.8% |
| 2022 | -15.6 | -1.0 | 27.5 | -10.0 | -46.3 | -47.5 | 9.0 | -24.7 | -12.7 | -5.2 | -35.2 | -18.6 | −90.3% |
| 2021 | 20.7 | 8.6 | 52.6 | -9.3 | -4.9 | 25.6 | -14.0 | 13.3 | -3.9 | 17.3 | -17.4 | 73.7 | +241.4% |
| 2020 | 0.0 | 0.0 | -23.1 | 50.0 | -6.7 | 50.0 | -14.3 | 261.1 | -1.5 | 9.4 | 51.4 | 36.8 | +1015.4% |
| 2019 | 57.1 | 0.0 | 0.0 | -4.5 | 4.8 | -9.1 | 0.0 | -15.0 | 0.0 | -41.2 | 40.0 | -7.1 | −7.1% |
| 2018 | 11.9 | -17.0 | 17.9 | -10.9 | -24.4 | 16.1 | -25.0 | -7.4 | 0.0 | -8.0 | -26.1 | -17.6 | −66.7% |
| 2017 | 16.7 | 57.1 | -9.1 | -10.0 | 55.6 | 7.1 | -3.3 | 0.0 | -20.7 | 8.7 | 32.0 | 27.3 | +250.0% |
| 2016 | 0.0 | 0.0 | 23.1 | -12.5 | 0.0 | 28.6 | -11.1 | -6.3 | 0.0 | 0.0 | 0.0 | -20.0 | −7.7% |
| 2015 | 5.3 | 0.0 | 5.0 | 0.0 | -14.3 | 0.0 | -5.6 | 0.0 | 0.0 | -11.8 | -6.7 | -7.1 | −31.6% |
| 2014 | 17.6 | 10.0 | 9.1 | 16.7 | -25.0 | 9.5 | 0.0 | -13.0 | -15.0 | -11.8 | 20.0 | 5.6 | +11.8% |
| 2013 | 0.0 | 6.7 | -6.3 | 13.3 | 0.0 | 0.0 | -5.9 | -6.3 | 0.0 | 6.7 | 12.5 | -5.6 | +13.3% |
| 2012 | 0.0 | -11.8 | 0.0 | 0.0 | 0.0 | 0.0 | -6.7 | 21.4 | -11.8 | -6.7 | 7.1 | 0.0 | −11.8% |
| 2011 | 0.0 | 6.7 | -6.3 | 6.7 | 0.0 | 18.7 | 15.8 | -22.7 | 5.9 | -5.6 | -5.9 | 6.2 | +13.3% |
| 2010 | -10.5 | 11.8 | -5.3 | 11.1 | 15.0 | 8.7 | -4.0 | -25.0 | 11.1 | -10.0 | -27.8 | 15.4 | −21.1% |
| 2009 | -12.5 | -14.3 | 33.3 | 12.5 | -11.1 | 25.0 | 20.0 | 50.0 | -11.1 | -18.8 | 38.5 | 5.6 | +137.5% |
| 2008 | -11.8 | 3.3 | -6.5 | -3.4 | -42.9 | 0.0 | 6.2 | -11.8 | -6.7 | -42.9 | -25.0 | 33.3 | −76.5% |
| 2007 | 7.5 | 2.3 | -2.3 | -7.0 | 0.0 | 2.5 | 12.2 | -8.7 | 2.4 | -9.3 | -15.4 | 3.0 | −15.0% |
No analyst coverage for this instrument.
Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America. The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for various diseases, including depression, anxiety, ADHD, PTSD, MCI, dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, ASD, and traumatic brain injury. It serves clinicians. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.